Krytantek

Phase 3Small molecule

AbbVie

Krytantek is one of 41 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Open-Angle GlaucomaActive, not recruiting

Ocular HypertensionPhase 3

Active, not recruiting

Open-Angle GlaucomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 2

Comparator: Pbo

Merck & Co.

Phase 3

2 3

Azopt

Novartis

Phase 3

1 4

Ocupress

AbbVie

Phase 3

1 5

LUMIGAN

AbbVie

Phase 3

2 6

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 7

Krytantek

AbbVie

Phase 3

2 8

Reference - LUMIGAN

AAmneal Pharmaceuticals, LLC

Phase 3

1 9

Duotrav

AAlcon Research

Phase 3

1 10

Combigan

EEMS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular Hypertension2 trials

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Completed·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT03257813·60 enrolled

Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Completed· AbbVie logo

AbbVie··NCT01737853·90 enrolled

Open-Angle Glaucoma1 trial

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)

Terminated·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT03193333·51 enrolled

MPA1 trial

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®

Completed·LLaboratorios Sophia S.A de C.V.·Phase 1·NCT03966365·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Krytantek. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Krytantek compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Krytantek. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Krytantek

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular Hypertension2 trials

Open-Angle Glaucoma1 trial

MPA1 trial

References

Drug Info

Quick Facts

Related News